2017-11-12T02:08:39-00:00 2016-12-31 KPMG LLP 1918 8th Avenue Suite 2900 Seattle WA 98101 990 2016-01-01 910653422 Benaroya Research Institute at Virginia Mason BENA 2063426500 1201 Ninth Avenue Seattle WA 981012795 Homer W Lane Jr Executive DirectorCFO 2017-10-23 true Sue Robison 2069134000 2017-10-23 204.147.223.1 2017-11-12 21:01:41 PS P 3583005D7428F592DDBE4235A0F9C55007128F9F 3583005D7428F592DDBE4235A0F9C55007128F9F 2016 2017-02-10 21:41:12Z Jane Buckner MD 1201 Ninth Avenue Seattle WA 98101 80832532 false X http://www.benaroyaresearch.org X 1956 WA To conduct and encourage high quality medical, surgical, and scientific research and research training in disease and problems of medical importance. 23 18 322 5 0 59709893 71346495 7021290 8553010 -107705 394767 347680 347680 66971158 80641952 23704570 29786250 0 25752883 25664449 0 0 18024768 19506635 67482221 74957334 -511063 5684618 85438161 91306270 45136173 44301004 40301988 47005266 X See Schedule O. false false 37109535 26975773 Immune Tolerance Network Program. See Schedule O. 7952552 1741940 Translational Program. See Schedule O. 6870598 754214 Diabetes Program. See Schedule O. 12479558 314323 8553010 64412243 true true false true false false false false false true true true false false false false true false false false true true false false false false false true false true true false false true false false false false false false false false false false false false true false false false false true 136 0 true 322 true false false false false false false false false false false X 23 18 false false false false true true true true true false false true true true true true true true true false WA X Homer W Lane Jr Executive DirectorC 2063426508 1201 Ninth Avenue Seattle WA 981012795 Jane Buckkner MD Ex Officio, President 040.00 X X 308899 0 25872 Carla Greenbaum MD Director 040.00 X 223629 0 30979 Joyce Lammert MD PhD Director 001.00 050.00 X 0 829016 98004 John Corman MD Director 001.00 050.00 X 0 572339 42318 Gary Kaplan MD Director 001.00 054.00 X 0 11562939 154309 Tom Cohen Director 001.00 X 0 0 0 Rebecca Campbell Director 001.00 X 0 0 0 Kristi Pangrazio Director 001.00 004.00 X 0 0 0 Margaret Morrow Director, Secretary 001.00 X X 0 0 0 Frank Dvorak PhD Director, Vice Chair 001.00 X X 0 0 0 Patricia Markey Director 001.00 X 0 0 0 Edward Drosdick Director 001.00 X 0 0 0 David Williams Director, Treasurer 001.00 X X 0 0 0 Ditman Johnson Director 001.00 X 0 0 0 W Michael Gallatin PhD Director 001.00 X 0 0 0 Jessica Muffett Director 001.00 X 0 0 0 Carla DewBerry Director, Chair 001.00 X X 0 0 0 Ann Sobil Director 001.00 X 0 0 0 Christopher Wilson MD Director 001.00 X 0 0 0 Nabil Istafanous Director 001.00 X 0 0 0 Ben Reiber Director 001.00 X 0 0 0 Jeffrey Wortley Director 001.00 X 0 0 0 Catherine Zimmerman Director 001.00 X 0 0 0 Homer Lane Jr Executive Director, CFO 040.00 X 322159 0 32946 Gerald Nepom MD PhD Former Ex Officio, Program Director, ITN 032.00 X 331403 0 44844 William Kwok PhD Research Member 040.00 X 223404 0 27072 Steven Ziegler PhD Director of Academic Affairs 040.00 X 214775 0 20690 James Lord MD Research Member 040.00 X 205666 0 21690 Lynn Rose Director Scientific Administration 040.00 X 187840 0 24542 2017775 12964294 523266 42 false true false Insight Globall LLC PO Box 198226 Atlanta GA 30384 Consulting 750789 KPMG LLP 1918 Eighth Ave Suite 2900 Seattle WA 98101 Auditing Consulting 113200 Riverbend Design Group LLC 414 Stewart St Suite 215 Seattle WA 98101 Consulting 133913 3 4000000 53520580 13825915 8038 71346495 Commercial Studies 621500 3604248 3604248 Collaborative research core services 621500 4948762 4948762 8553010 394767 394767 538260 190580 347680 347680 347680 80641952 8553010 742447 27117157 27117157 0 2669093 2669093 0 862902 426726 436176 0 18971336 14133576 4837760 1458076 1046994 411082 3017389 2166683 850706 1354746 972797 381949 0 14055 14055 93500 93500 0 0 3028628 2319583 709045 49177 49177 120642 24353 96289 1871865 891496 980369 0 2683292 2331358 351934 306847 258954 47893 0 109201 91046 18155 822184 715300 106884 0 3479492 2775138 704354 43687 43687 Supplies 4063445 3931380 132065 Other Purchased Services 340411 169889 170522 Patient Costs 1291625 1291625 Research Participants Fee 429580 429580 759004 649515 109489 74957334 64412243 10545091 0 9334155 10525094 6095 2288001 11688324 12690871 854913 1620548 454115 349640 72050010 42450877 30955262 29599133 9139241 5312100 22130376 28068298 875680 852585 85438161 91306270 12044459 12436607 4410224 4142907 9425000 27721490 19256490 45136173 44301004 X 20378881 20816818 8690843 12225413 11232264 13963035 40301988 47005266 85438161 91306270 5684618 1018660 X false true X true true true X Virginia Mason Medical Center Seattle WA 38329362 44973133 54174085 59709893 71346495 268532968 38329362 44973133 54174085 59709893 71346495 268532968 24906893 243626075 560734 642011 707157 430555 933027 3273484 4701834 6122655 6639555 7021290 8553010 33038344 304844796 0.79920 0.78320 X 0.00000 0.00000 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 163134 112648 275782 74957334 1503935718 74957334 1504211500 1000000 1000000 250000 250000 1000000 1000000 1000000 1000000 4000000 6000000 122035 138835 154766 275782 691418 250000 250000 250000 250000 1000000 1500000 114035 119335 108173 163134 504677 false false false false false false false false false false false II-A A Benaroya Research Institute at Virginia Mason, EIN 91-0653422, 1201 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 40. II-A A continued Virginia Mason Health System, EIN 91-1351110, 1100 Ninth Avenue, Seattle, WA 998101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0. II-A A continued Virginia Mason Institute, EIN 26-3763656, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. 0 Excess Lobbying Expenditures. II-A A continued Virginia Mason Medical Center, EIN 91-0565539, 1100 Ninth Avenue, Seattle, WA 98101. Electing member. Grassroots Lobbying Expenditures 121,040 Direct Lobbying Expenditures 52,648. Excess Lobbying Expenditures 0. Tax year ending December 31, 1998 was the first year in which Virginia Mason Medical Center made the election under Section 501h. The election was not revoked before the start of the tax year ending December 31, 2016. II-A A continued Yakima Valley Memorial Hospital Association, EIN 91-0567263, 2811 Tieton Drive, Yakima, WA 98902. Non-electing member. Grassroots Lobbying Expenditures 42,094 Direct Lobbying Expenditures 60,000. Excess Lobbying Expenditures 0. false false true true 756906 756906 49143699 24861836 24281863 196862 196862 21697346 17392179 4305167 255197 255197 29599133 Financial derivatives and other financial products Closely-held equity interests Interest in Net Assets of Virginia Mason Health System 28068298 F 28068298 Federal income taxes 81660612 1018660 1018660 80641952 80641952 74957334 74957334 74957334 true East Asia and the Pacific Conferences Medical Research 5066 Europe Including Iceland and Greenland Conferences Medical Research 27913 South America Conferences Medical Research 283 33262 33262 Europe Including Iceland and Greenland Medical Research 48125 Wire Transfer Europe Including Iceland and Greenland Medical Research 547049 Wire Transfer Europe Including Iceland and Greenland Medical Research 853701 Wire Transfer Europe Including Iceland and Greenland Medical Research 60534 Wire Transfer Europe Including Iceland and Greenland Medical Research 47312 Wire Transfer Europe Including Iceland and Greenland Medical Research 11744 Wire Transfer Europe Including Iceland and Greenland Medical Research 191203 Wire Transfer North America Medical Research 29292 Wire Transfer North America Medical Research 488253 Wire Transfer North America Medical Research 138963 Wire Transfer North America Medical Research 79571 Wire Transfer North America Medical Research 99896 Wire Transfer North America Medical Research 73450 Wire Transfer 13 false false false false false false Part I Line 2 Subrecipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing federal grants. The Subrecipient Monitoring Policy provides assurance that subrecipients comply with federal grant regulations. This policy sets the criteria to establish eligibility of subrecipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of subrecipient internal controls and a standardized risk assessment is presented to management on each subrecipient. A Management Letter is issued to each subrecipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring subrecipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. Part I Line 3f The expenditures were actual expenses incurred in the region based on individual expense reports and tracking of expenditures by grant or department on the accrual basis of accounting. Part II Line 1 The expenditures were expenses incurred in the region based on award goals on the accrual basis of accounting. true Ann&Robert H Lurie Children's Hospital of Chicago 225 East Chicago Ave No 205 Chicago IL 606112991 362170833 501c3 24908 Medical Research Arizona State University Office for Research and Sponsored P Tempe AZ 852876011 860196696 Arizona 36721 Medical Research Arkansas Children's Hospital Research Institute One Childrens Way Financial Service Little Rock AR 722023591 710694931 501c3 70483 Medical Research Asthma Inc 9725 3rd Ave NE Suite 500 Seattle WA 98115 237219813 501c3 442875 Medical Research Baylor Research Institute 3301 Live Oak Suite 501 Dallas TX 75204 751921898 501c3 45742 Medical Research Baylor College of Medicine 7200 Cambridge St 9th Floor Houston TX 77030 741613878 501c3 13547 Medical Research Brigham And Women's Hospital Bank of America NA POBox 3887 Boston MA 022413887 042312909 501c3 249272 Medical Research Case Western Reserve University 10900 Euclid Avenue Nord Hall Suite Cleveland OH 441067037 341018992 501c3 33617 Medical Research Columbia University Trustees of PO Box 29789 General Post Office New York NY 100879789 135598093 501c3 378068 Medical Research Dana-Farber Cancer Institute Inc 450 Brookline Ave 431C Boston MA 02215 042263040 501c3 223659 Medical Research Denver Nephrologists PC 130 Rampart Way Suite 300B Denver CO 80230 840591433 15602 Medical Research Dermatology Research Assoc Inc 301 Carriage Place Manhatten Beach CA 90266 273947370 96549 Medical Research Duke University PO Box 602651 Accounts Receivable L Charlotte NC 282602651 560532129 501c3 441237 Medical Research Emory University 1599 Clifton Road NE 4th floor Atlanta GA 30322 580566256 501c3 337707 Medical Research Feinstein Institute for Medical Research 350 Community Drive Manhasset NY 11030 112673595 501c3 63424 Medical Research Fred Hutchinson Cancer Research Center 1100 Fairview Ave N J6-330 PO Box 1 Seattle WA 981091024 237156071 501c3 32609 Medical Research Hospital for Special Surgery 535 East 70th Street New York NY 10021 131624135 501c3 29423 Medical Research Icahn School of Medicine at Mount Sinai One Gustave L Levy Place Box 3500 O New York NY 100296574 136171197 501c3 228337 Medical Research Indiana University 400 E 7th St Poplars Room 501 Bloomington IN 47405 356001673 501c3 100375 Medical Research Johns Hopkins University Central Lockbox c/o B of A 12529 Co Chicago IL 60693 520595110 501c3 1637275 Medical Research Jonathan Corren MD Inc 10780 Santa Monica Blvd 280 Allergy Los Angeles CA 90025 462346264 334001 Medical Research Joslin Diabetes Center One Joslin Place Boston MA 022155306 042203836 501c3 78804 Medical Research Lahey Clinic Inc 41 Mall Rd Attn Office of Research Burlington MA 01805 042704683 501c3 26418 Medical Research La Jolla Institute for Allergy & Immunology 9420 Athena Circle La Jolia CA 92037 330328688 501c3 77979 Medical Research Massachusetts General Hospital 55 Fruit Street Research Management Boston MA 02114 042697983 501c3 5435581 Medical Research Medical College of Wisconsin Accounts Receivable PO Box 26509 Milwaukee WI 532260509 390806261 501c3 69333 Medical Research Medical University of South Carolina 19 Hagood Avenue Ste 604 MSC 808 Charleston SC 29425 576000722 South Carolina 59703 Medical Research National Jewish Health 1400 Jackson Street M213 Denver CO 80206 742044647 501c3 141079 Medical Research New York University-School of Medicine PO Box 415026 Bank of America Boston MA 022415026 135562308 501c3 259762 Medical Research Northwestern University 750 N Lake Shore Drive Chicago IL 60611 362167817 501c3 694031 Medical Research Ohio State University Office of Sponsored Programs 1960 K Columbus OH 43210 316025986 501c3 29096 Medical Research Oklahoma Medical Research Foundation 825 NE 13th Street Oklahoma City OK 73104 730580274 501c3 159942 Medical Research Polyclinic Madison Center 904 7th Ave 6th Floo Seattle WA 98104 910369070 19760 Medical Research Rockefeller University 1230 York Ave Financial Post Award New York NY 100656307 131624158 501c3 181417 Medical Research Rogosin Institute 505 East 70th Street 2nd Floor New York NY 100214872 133184198 501c3 17639 Medical Research Rutgers the State University of New Jersey Office of Research and Sponsored Pr New Brunswick NJ 089018559 226001086 501c3 491506 Medical Research Sanford Research 2301 E 60th St N Attn Clinical Rese Sioux Falls SD 57104 460450378 501c3 76491 Medical Research Seattle Childrens Hospital PO Box 24728 Seattle WA 981240728 910564748 501c3 137110 Medical Research Stanford University PO Box 44253 San Francisco CA 941444253 941156365 501c3 833372 Medical Research State University of Iowa 105 Jessup Hall Iowa City IA 52242 426004813 Iowa 10892 Medical Research St Jude Children's Research Hospital Inc PO Box 1000 Dept 949 Memphis TN 381480949 620646012 501c3 223994 Medical Research Swedish Health Services - Swedish Physicians LLC Swedish MC - Research Center PO Box Seattle WA 981249845 911942315 15100 Medical Research Tulane University 1430 Tulane Ave Dermatology 8036 At New Orleans LA 70112 720423889 501c3 82816 Medical Research University of Miami PO Box 025405 Location 3 Miami FL 331025405 590624458 501c3 7724 Medical Research University of Washington Box 94224 Seattle WA 981246524 916001537 501c3 582216 Medical Research University of Michigan Box 223131 Pittsburgh PA 152512131 386006309 501c3 90525 Medical Research University of Utah Utah Diabetes Center 615 Arapeen D Salt Lake City UT 84108 876000525 501c3 64322 Medical Research Univ of Minnesota Regents 450 McNamara Alumni Center 200 Oak Minneapolis MN 554552070 416007513 Minnesota 61814 Medical Research Univ of Texas SW Med Ctr Grants Management PO Box 841753 Dallas TX 752841753 756002868 Texas 66724 Medical Research University of Colorado-Denver PO Box 910238 Denver CO 802910238 846000555 501c3 1947529 Medical Research University of Chicago Section Of Endocrinology 5841 S Mar Chicago IL 60637 362177139 501c3 267199 Medical Research University of California The Regents of Accounting Office CGA Box 0897 San Francisco CA 941430897 946002123 501c3 13586 Medical Research University of Pittsburgh 200 Lothrop St E1140 Biomedical Sci Pittsburgh PA 15213 250965591 501c3 424490 Medical Research University of Oklahoma Dept of ORL PO Box 26901 WP-1290 Oklahoma City OK 731269818 731377584 501c3 109130 Medical Research University of Pennsylvania PO Box 785541 Philadelphia PA 171785541 231352685 501c3 174137 Medical Research University of Florida Board of Trustees PO Box 113001 Gainesville FL 32611 596002052 501c3 33041 Medical Research University of Nebraska Medical Center 985045 Nebraska Medical Center Omaha NE 681985045 470049123 501c3 36607 Medical Research University of Maryland Baltimore Sponsored Projects Acctng 220 Arch Baltimore MD 212011508 526002033 Maryland 18713 Medical Research University of North Carolina at Chapel Hill PO Box 402420 Bank of America Lockb Atlanta GA 303842420 566001393 501c3 694818 Medical Research University of Texas MD Anderson Cancer Ctr PO Box 4390 Grants Contract Acctng Houston TX 772104390 746001118 501c3 11923 Medical Research University of Wisconsin Madison Board of Regents 600 Highland Ave F8/138 CSC Madison WI 53792 396006492 501c3 389888 Medical Research University of California San Francisco Controllers Office Contract Grants San Francisco CA 941430897 946036493 501c3 7304374 Medical Research University of Alabama at Birmingham 1720 2nd Ave South AB 990 Birmingham AL 35294 636005396 Alabama 24499 Medical Research University of North Carolina at Greensboro 2511 MHRA Building PO Box 26170 Greensboro NC 274026170 566001468 501c3 58271 Medical Research University of California Los Angeles 11000 Kinross Ave Ste 211 Los Angeles CA 90095 956006143 501c3 93170 Medical Research Vital Prospects Clinical Research Institute PC 7307 S Yale Ave Suite 200 Tulsa OK 74136 261814411 24194 Medical Research Wake Forest University Health Sciences Medical Center Boulevard WinstonSalem NC 27157 223849199 501c3 35009 Medical Research Western Michigan University School of Medicine PO Box 50391 Kalamazoo MI 490050391 454135256 501c3 7758 Medical Research Winthrop University Hospital Dept of Finance 700 Hicksville Road Bethpage NY 11714 111633486 501c3 33147 Medical Research Yale University Grant and Contract Financial Admini New Haven CT 065081873 080648973 501c3 583741 Medical Research 64 6 Part I Line 2 Subrecipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing federal grants. The Subrecipient Monitoring Policy provides assurance that subrecipients comply with federal grant regulations. This policy sets the criteria to establish eligibility of subrecipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of subrecipient internal controls and a standardized risk assessment is presented to management on each subrecipient. A Management Letter is issued to each subrecipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communciated with an educated administrative staff regarding implementation of this policy. Part I Line 2 continued The Director of Grants and Contracts is responsible for monitoring subrecipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. X true true false true false false false false false false false Jane Buckkner MD Ex Officio, President 308999 24000 1872 334871 Carla Greenbaum MD Director 223629 24000 6979 254608 Joyce Lammert MD PhD Director 453400 120892 254724 86450 11554 927020 126000 John Corman MD Director 553925 18414 19643 22675 614657 Gary Kaplan MD Director 1066494 441298 10055147 111126 43183 11717248 8352547 Homer Lane Jr Executive Director, CFO 254665 67494 24000 8946 355105 Gerald Nepom MD PhD Former Ex Officio, Program Director, ITN 228626 102777 42000 2844 376247 William Kwok PhD Research Member 222839 565 24000 3072 250476 Steven Ziegler PhD Director of Academic Affairs 214211 565 16334 4356 235466 James Lord MD Research Member 205666 17634 4056 227356 Lynn Rose Director Scientific Administration 187275 565 19148 5394 212382 Part I Line 3 Benaroya Research Institute at Virginia Mason BRI delegates to Virginia Mason Health Systems its parent and sole member Board Compensation and Benefits Committee, a committee composed of independent Health System Board members to whom the BRI Board has delegated the authority to approve all compensation and benefits for the executive leaders of BRI. To ensure that such benefit plans are market competitive and reasonable, the Committee receives support and advice, including appropriate market comparability data from an independent compensation consultant with expertise in the health care industry and access to relevant market data. See Schedule O for additional disclosure. Part I Line 4b The Virginia Mason Medical Center has a Supplemental Executive Retirement Plan SERP in which certain BRI Executives particpate. The SERP is a 457 f nonqualified deferred compensation plan pursuant to which plan benefits are subject to a substantial risk of forfeiture, entered into in connection with certain senior executives joining the Medical Center. The plan was approved by the Boards Compensation and Benefits Committee, a committee composed of independent board members to whom the Board delegates the authority to approve compensation and benefits to the Medical Centers most senior executives. The Committee receives advice from an independent compensation consultant to ensure that compensation and benefits, including the SERP, are market competitive and reasonable. Supplemental Executive Retirement Plans such as this are customary for senior executives in the health care industry. Part I Line 4b Gary Kaplan, M.D. received a payment of 10,031,813 from a Supplemental Executive Retirement Plan. Joyce Lammert, M.D. received a 234,438 payout from a Supplemental Executive Retirement Plan. Gary Kaplan M.D. accrued benefits in a Supplemental Executive Retirement Plan of 96,280. Joyce Lammert, M.D. accrued benefits in a Supplemental Executive Retirement Plan of 63,000. A WA Econ Devel Fin Auth-2012 Series B 911493002 2012-06-01 10390000 See Part VI false true false B WA Econ Devel Fin Auth-Series 2016 911493002 2016-06-01 18631490 See Part VI false true false A 1300000 10390348 2550348 7840000 2013 true false true true B 18631490 18631490 true false true true A false true false true true 0.01180 0.01180 false false true B false true false true true 0.01180 0.01180 false false A false true false false false false true B false true false false false false true A true B true Part I Line A Column F Purposes to currently refund WEDFA Series 2006C bonds issued 11/15/2006, and to fund research facility improvements. Part I Line B Column F Purposes to currently refund WEDFA Series 2012A taxable bonds issued 06/01/2012. No tax-exempt private activity bonds are being refunded. Part II Line 3 Column A Difference between Part I, column e and Part II, Line 3 is investment earnings. Form 990, Part III, Line 1 Benaroya Research Institute at Virginia Mason BRI is a world-renowned medical research institute whose work has resulted in major advances in our understanding of autoimmune and immune-mediated diseases. BRI is affiliated with the Virginia Mason Health System, which provides governance oversight and development support through the Virginia Mason Foundation. In 2016, BRI researchers generated 90 scientific publications that were published in prestigious research journals and delivered 94 presentations at domestic and international research conferences. One in 15 Americans suffers from an autoimmune disease and many suffer from more than one. These diseases include type 1 diabetes, multiple sclerosis, Crohns disease and rheumatoid arthritis to name a few. Even more Americans, one out of every four, suffer from other immune-mediated diseases, allergy and asthma. Because these diseases are connected by common destructive pathways, research on one or two immune system diseases has far reaching implications for the whole spectrum of immune-mediated disease. As a world leader in scientific innovation, BRIs discoveries are having significant impact on people living with these diseases today-by improving the ability to predict disease risk, prevent onset of disease, decrease disease progression and make treatments safer and better. Form 990, Part III, Line 4 One of the unique qualities of BRI is the close integration of three types of medical research - laboratory research, translational research and clinical research - to improve peoples lives. Our scientists can address both the basic science issues and clinical applications, which is the best way to design studies with the highest potential for success. For BRI, discovery starts in the laboratory. 2016 advancements in translational, immunology, clinical research and other areas are highlighted below. Form 990, Part III, Line 4a Funding for the Immune Tolerance Network ITN was awarded to BRIs Dr. Jerry Nepom in 2014 from the National Institute of Allergy and Infectious Disease NIAID of the National Institutes of Health NIH. The 7-year award, totaling 27 million annually supports the ITN, a research consortium established in 1999 with a primary focus on the development of new tolerogenic approaches for the treatment and prevention of disease in three clinical areas asthma and allergic diseases autoimmune diseases and immune-mediated rejection of transplanted solid organs, tissues and cells. As the Prime recipient of this grant, BRI is responsible for the overall management of the grant from NIAID including oversight of all aspects of the Networks infrastructure. The major activities in 2016 were diverse, but continued to center on preserving the ITNs cohesive project focused environment and its framework which has proven so successful in the management of a large cooperative agreement grant. Key outcomes in 2016 include the following 1 Cross Network Integration A top priority in this reporting period was to continue the successful ITN infrastructure which is spread across three main operational sites. This required careful planning and collaboration as the ITNs major centers of operations are geographically diverse, located in Seattle, San Francisco and Bethesda. Few changes were made to the existing network integration as the current model continues to successfully support the overall ITN program. Establishing new relationships and vital connections within the research community continued to be an ITN goal. 2 Operations and Clinical Trial Support The ITN program team at BRI issued 161 subawards in 2016 in support of 20 active ITN clinical trials and numerous supporting ITN mechanistic trials. 3 Supplemental Funding / Partnerships ITN central administration continued to focus on identifying additional opportunities for supplemental funding and/or funding partnerships. a Supplemental Funding Opportunities The ITN Program Team at BRI submitted one supplemental funding request in 2016. This request was awarded, bringing in an additional 4.9M in funding to the ITN BRI. b Partnerships The ITN continued its relationship with pharmaceutical partners for partial funding for two ITN studies with NIAID as the clinical sponsor. 4 Publication Activity In 2016, 25 ITN publications were published in prestigious research journals and were presented at domestic and international research conferences. These publications represented ITN research in all therapeutic focus areas Type 1 Diabetes, Transplant, Autoimmune disease and Allergy and Asthma. Form 990, Part III, Line 4b Translational research is a scientific approach that allows research observations made at the bench to be quickly tested in patients, at the bedside and brought back to the bench again in an expedient and systematic way. This research is translating new methods that improve our ability to predict disease risk, prevent onset of disease, decrease disease progression and make treatments safer and better. The research emphasis of the BRI Translational Research Program is the area of autoimmune and immune-mediated diseases. BRI scientists and physician collaborators work together to study blood and serum samples along with medical and demographic data collected from people with autoimmune and immune-mediated diseases. These include multiple sclerosis, type 1 diabetes, lupus, rheumatoid arthritis, inflammatory bowel disease, allergy and asthma. BRI maintains an extensive biorepository with samples dating back to 2000, including seven disease categories and a biorepository of healthy people for comparison purposes. Advancements in 2016 include the following 1 Connecting Cancer to Immunotherapy Research - In addition to autoimmune disease research, BRI scientists are actively investigating new cancer immunotherapies as a means of understanding the underlying causes of autoimmunity. Many cancer patients treated with specific immune-therapeutics have been observed to develop autoimmune syndromes, many of them long-lasting. This research is being conducted in partnership with Virginia Mason Medical Center. A major component of this research is the development of a robust tissue repository that includes tumor samples, blood samples and demographic data from patients with a variety of cancer types including pancreatic, colorectal, lung and breast tumors. 2 Translational Research Symposium - The annual Clinical and Translational Research Symposium, sponsored by the Wilske Center for Translational Research, took place at Virginia Mason Medical Center. The event connected researchers and clinicians by highlighting the range of clinical and translational research being conducted at BRI. Of the more than 60 research abstracts submitted, the Wilske committee selected the top eight abstracts for oral presentation. 3 Gene Editing - BRI and Seattle Childrens Research Institute SCRI are collaborating on a preclinical study pioneering the use of gene editing techniques in efforts to control type 1 diabetes. To attack this complex problem, BRI is combining its regulatory T cell expertise with SCRIs gene editing expertise. 4 Studying Rheumatoid Arthritis RA - BRI continues its research into studying how RA starts and progresses, and have found the disease begins years before clinical signs and symptoms are apparent. The goal is to understand the disease so it can be prevented before it even starts. Researach into monitoring disease activity during therapy and predicting patient drug responses are also underway. 5 Understanding Antigen-Specific T Cells - Using single-cell RNA sequencing, researchers are investigating T cell receptors and genes expressed by antigen-specific T cells. This could pave the way to monitor, treat and prevent diseases like type 1 diabetes. Form 990, Part III, Line 4c BRI is dedicated to seeking ways to eliminate type 1 diabetes, while at the same time looking for therapies to prevent, reverse and intervene in the disease at all stages. BRI is an international leader in type 1 diabetes research and has investigated it for more than 30 years, starting with identification of a genetic marker for the disease. BRI continues to lead the Type 1 Diabetes TrialNet, a National Institutes of Health-funded clinical trial network for type 1 diabetes prevention and early treatment. BRI also serves as the TrialNet Hub that includes 23 clinical centers working in cooperation with more than 200 screening and clinical research sites throughout the U.S. and six other countries. Form 990, Part III, Line 4d 1 Clinical Research Program Benaroya Research Institute oversees all clinical research at Virginia Mason Medical Center which uniquely combines the expertise of a world-renowned medical research institute with the remarkable care of a healthcare quality leader. The BRI Clinical Research Program supports Virginia Mason Medical Center clinical investigators in studies across a wide variety of diseases and conditions, such as cardiology and cancer. Each year the Clinical Research Program staff enrolls more than 1500 study participants in Virginia Mason Medical Center trials. This program involves approximately 170 research investigators, oversees 440 active studies and has 135 studies currently open to enrollment. 2 Immunology Research Program a Leadership of Asthma and Allergic Diseases Cooperative Research Center - BRI received a five-year grant from the National Institute of Allergy and Infectious Diseases to study the immune systems responses to allergens in the lungs. Investigators at BRI, University of Washington Medicine and Seattle Childrens Research Institute will collaborate to gain insights into the lung epithelium. Dr. Steve Ziegler will lead the project along with eight other principal investigators from the other two institutions. b Understanding cell communication in the gut by studying special rare cells which organize communications, to understand how they can cause inflammatory bowel disease. c Developing new experimental models to understand how the oral drug fingolimod works in multiple sclerosis at a molecular level and how it is modulating different cells of the immune system. Does the drug work differently in different people and on different immune cells Eventually this information will help clinicians to match the right drug to the right person at the right time. d Lung in a Dish - In collaboration with Seattle Childrens Research Institute SCRI scientists at BRI have created a modeling system of the human lung in a laboratory dish to study asthma, allergies and respiratory diseases in children. They hope to understand mechanisms that drive childhood asthma, which will lead to novel therapies for this common condition. e Critical Discovery in Peanut Allergy - Scientists at BRI recently discovered a critical pathway in peanut allergy that may extend to other food allergies. The pathway is triggered by Interleukin 33 IL-33, a protein that helps drive the immune response that promotes allergic reactions to a substance, such as peanuts, that in most people is generally harmless. f Discovering a Biomarker to Fight Allergies - Scientists are pioneering new allergy research using a rare type of immune cell, called TH2A, identified at BRI that is associated with all allergic diseases. g T Cell Response to Different Challenge - Researchers are working to pinpoint how T cells tailor their response to different challenges, since its becoming clear that T cells play a role not just in fighting infections, but in things as diverse as Alzheimers disease, obesity, and wound repair. h Studying the P13-Kinase Enzyme-Scientists are now taking a closer look at how P13-kinase pathways activate T cells and influence how they develop as well as what happens when this process malfunctions. The P13-kinase work is part of their effort to generate insights that could eventually lead to improved therapies for both fighting cancer and stopping autoimmune diseases. 3 Matrix Biology Research Program a The Pathogenic Nature of the Extracellular Matrix in Rheumatoid Arthritis - Scientists are working to discover whether the extracellular matrix and two of its components, hyaluronan and versican, are remodeled differently in the joint synovium of rheumatoid arthritis patients compared to that of osteoarthritis patients and whether these differences lead to a more pervasive and heightened form of inflammation in RA as compared to OA synovium. b Mechanisms of Inflammation in Viral-triggered Asthma - Working with immunologists and physician-scientists at Seattle Childrens Research Institute, matrix biologists are investigating mechnisms responsible for airway extracellular matrix dysregulation in asthma, and the resulting increased adhesion and activation of leukocytes. Form 990, Part VI, Section A, Line 1a The governing body delegates to an Executive Committee comprised of four officers of the Board and the Chairs of each standing Board Committee, the authority of the Board of Directors in the management of the corporation as may be deemed by the Executive Committee to be appropriate, to be exercised in time periods between regularly scheduled meetings of the Board of Directors provided that the Executive Committee has the authority to act only in time sensitive or emergency situations. The Director and the Executive Director of the corporation serve as ex officio members of the Executive Committee without voting rights. The Executive Committee does not have the authority to amend, alter or repeal the bylaws elect, appoint or remove any member of such Executive Committee or any director or officer of the corporation amend the articles of incorporation adopt a plan of merger or adopt a plan of consolidation with another corporation authorize the sale, lease or exchange of all or substantially all the property and assets of the corporation not in the ordinary course of business authorize the voluntary dissolution of the corporation or revoke proceedings therefore adopt a plan for the distribution of the assets of the corporation or amend, alter or repeal any resolution of the Board which by its terms provides that it shall not be amended, altered or repealed by such Executive Committee. The Executive Committee also serves as the planning committee for the Board of Directors and oversees any compliance issues raised by the Board of Directors. Form 990, Part VI, Section A, Line 6, 7 Virginia Mason Health System VMHS is the sole corporate member of Benaroya Research Institute at Virginia Mason BRI. VMHS as the sole voting member has the following approval rights a election or appointment of Directors and Officers of the Board of Directors b removal of Directors and Officers of the Board of Directors including any executive officer of the corporation c approval of all long-range and short-range plans proposed by the Board of Directors d approval of the annual capital and operating budgets proposed by the Board of Directors e approval of the borrowing of funds where the amount borrowed is in excess of Five Hundred Thousand Dollars 500,000 f approval of the sale, lease, exchange, mortgage, pledge or disposal of all or substantially all of the property and assets g approval of all amendments to or repeal of the Agreement Association or the Bylaws of the corporation h all other rights and powers as specified in the Washington Nonprofit Corporation Act. Form 990, Part VI, Section B, Line 11b The VMHS Audit and Compliance Committee ACC, a committee composed of independent community members has been delegated responsibility for oversight of the annual Form 990 preparation process including a selection, engagement, and review of the performance of the independent tax preparer b review of the annual draft Form 990 tax return, and c recommendation of the final Form 990 tax return for review to the BRI Board of Directors. Annually, at the September meeting, management and the tax preparer provides the ACC with an initial draft of the Form 990 and present an overview of the Form 990 preparation process. The final draft Form 990 is reviewed and approved by the ACC in November followed by a Board review of the final Form 990 prior to filing. The final Form 990 tax return is provided to each member of the Board of Directors via electronic delivery. Form 990, Part VI, Section B, Line 12c The VMHS Governance Committee has been delegated accountability for oversight of the process for disclosure, evaluation and management of conflict of interest involving any member of the BRI Board of Directors, executive leadership or key employees Covered Person. Pursuant to the Conflict of Interest Policy, an annual conflict of interest questionnaire is distributed to all Covered Persons. In addition, a Covered Person has an on-going duty to disclose the existence of a conflict of interest at any time an actual or potential conflict arises. Each Covered Person is required upon appointment and annually thereafter to attest to a statement that affirms that such person has a received a copy of the Conflict of Interest Policy b has read and understands the Policy c has agreed to comply with the Policy and d understands that BRI is a charitable organization and that in order to maintain its federal tax exemption must engage in activities that accomplish its tax-exempt purposes. Written disclosures are reviewed by the Governance Committee to determine if an actual or potential conflict of interest exists and if so, how it should be managed. The Covered Person is informed in writing regarding the determination the Conflict of Interest Management Plan. No Covered Person with an actual or potential conflict of interest shall engage in an activity on BRIs behalf related to the disclosed actual or potential Conflict of Interest unless such activity is permitted by the Conflict of Interest Management Plan or until the Covered Person has undertaken all steps set forth in the Management Plan to manage, reduce or eliminate the conflict. All Covered Persons have a duty to disclose the existence of any actual or potential conflict of interest with respect to meeting agenda items. The Conflict of Interest Policy requires that copies of the Conflict of Interest Questionnaire be completed annually by each covered Person and any Conflict of Interest Management Plan be maintained. Form 990, Part VI, Section B, Line 15 The VMHS Compensation and Benefits Board Committee, a committee composed solely of independent directors none of whom have a conflict of interest, is accountable for setting reasonable total compensation packages for each executive, officer and key employee of BRI Executives consistent with BRIs compensation philosophy and principles. The Committee approves annual goals and performance criteria which are used in determining merit increases and variable compensation opportunities. The Committee assesses performance against these goals. The Committee selects and engages a qualified independent compensation consultant to review and analyze the total compensation and benefits packages of the Executives. The Committee as part of its analysis obtains from the compensation consultant appropriate comparability data including total compensation paid by similarly situated organizations for positions that are functionally comparable to each of the Executives. The Committee will consider the significant terms of the agreement with each Executive including the total compensation to be paid and the employees duties and responsibilities. Consistent with the compensation philosophy and principles, the Committee approves total compensation packages for each of the Executives based on information presented to the Committee, reasonableness and the best interest of BRI. The Committees decisions regarding compensation for each Executive are documented in written resolutions and minutes of the Committee. The Committee promptly reports its actions to the VMHS board which reports are reflected in the Boards minutes. The individual positions who were reviewed in 2016 were the Board Director, Carla Greenbaum, BRI Director, and Executive Director and Chief Financial Officer. Form 990, Part VI, Section C, Line 19 The organizations Articles, Bylaws, Conflict of Interest Policy and financial statements are made available upon request. Virginia Mason Health Sysstem (VMHS) 1100 Ninth Ave Seattle WA 98101 911351110 Fundraising WA Sec 501c3 7 NA true Virginia Mason Medical Center 1100 Ninth Ave Seattle WA 98101 910565539 Health Care WA Sec 501c3 3 VMHS false Virginia Mason Institute 1100 Ninth Ave Seattle WA 98101 263763656 Education/Research WA Sec 501c3 9 VMMC false Yakima Valley Memorial Hospital Association 2811 Tieton Drive Yakima WA 98902 910567263 Health Care WA Sec 501c3 3 VMHS false false false true false false false false false false true true false false true false true true false false Benaroya Research Institute at Virginia Mason 1201 Ninth Avenue Seattle WA 98101 910653422 0 0 0 74957334 74957334 49832 12458 0 0 0 Virginia Mason Health System 1100 Ninth Avenue Seattle WA 98101 911351110 0 0 0 21623749 21623749 14375 3594 0 0 0 Virginia Mason Medical Center 1100 Ninth Avenue Seattle WA 98101 910565539 X 121040 52648 173688 984139233 984312921 654371 163593 0 0 0 Virginia Mason Institute 1100 Ninth Avenue Seattle WA 98101 263763856 0 0 0 7100623 7100623 4720 1180 0 0 0 Yakima Valley Memorial Hospital Association 2811 Tieton Drive Yakima WA 98902 910567263 42094 60000 102094 416114779 416216873 276701 69175 0 0 0